Needham Reiterates Buy on Praxis Precision Medicine, Maintains $151 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Praxis Precision Medicine (NASDAQ:PRAX) and maintained a price target of $151.
September 05, 2024 | 10:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Praxis Precision Medicine and maintained a price target of $151, indicating confidence in the company's future performance.
The reiteration of a Buy rating and a high price target by a reputable analyst suggests positive sentiment and potential upside for PRAX, likely boosting investor confidence and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100